West Nile Virus Infections - Pipeline Review, H1 2015

Published: Apr, 2015 | Pages: 55 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

West Nile Virus Infections - Pipeline Review, H1 2015

Summary 

Global Markets Direct's, 'West Nile Virus Infections - Pipeline Review, H1 2015', provides an overview of the West Nile Virus Infections's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for West Nile Virus Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for West Nile Virus Infections and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of West Nile Virus Infections
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for West Nile Virus Infections and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the West Nile Virus Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the West Nile Virus Infections pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reason To Buy 

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for West Nile Virus Infections
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding West Nile Virus Infections pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
West Nile Virus Infections Overview 7
Therapeutics Development 8
Pipeline Products for West Nile Virus Infections - Overview 8
Pipeline Products for West Nile Virus Infections - Comparative Analysis 9
West Nile Virus Infections - Therapeutics under Development by Companies 10
West Nile Virus Infections - Therapeutics under Investigation by Universities/Institutes 11
West Nile Virus Infections - Pipeline Products Glance 12
Clinical Stage Products 12
Early Stage Products 13
West Nile Virus Infections - Products under Development by Companies 14
West Nile Virus Infections - Products under Investigation by Universities/Institutes 15
West Nile Virus Infections - Companies Involved in Therapeutics Development 16
BioDiem Ltd 16
CalAsia Pharmaceuticals, Inc. 17
CEL-SCI Corporation 18
GlaxoSmithKline plc 19
Kineta, Inc. 20
West Nile Virus Infections - Therapeutics Assessment 21
Assessment by Monotherapy Products 21
Assessment by Target 22
Assessment by Mechanism of Action 24
Assessment by Route of Administration 26
Assessment by Molecule Type 27
Drug Profiles 29
BG-323 - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
CEL-1000 - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
EMER-IT - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
ETX-112 - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
HydroVax-001 - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
Innate Immune Adjuvants - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
Innate Immune Agonists - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
Monoclonal Antibodies for West Nile Virus Infections - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
Monoclonal Antibody for West Nile Virus Infections - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
rOAS - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
Small Molecule to Inhibit NS2B-NS3 Protease for Dengue and West Nile Virus Infection - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
Small Molecule to Inhibit NS3 Protease for Dengue and West Nile Virus Infections - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
Small Molecule to Inhibit NS5 for Dengue and Flavivirus Infections - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
Small Molecules for West Nile Virus Infections - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
Small Molecules to Inhibit NS3 Protease for Dengue and West Nile Virus Infections - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
Small Molecules to Inhibit Serine Protease for Viral Infections - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
Synthetic Peptides for West Nile Virus and Dengue Virus Infections - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
west nile vaccine - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
west nile virus vaccine - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
west nile virus vaccine 2 - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
West Nile Virus Infections - Recent Pipeline Updates 50
West Nile Virus Infections - Dormant Projects 51
West Nile Virus Infections - Product Development Milestones 53
Featured News & Press Releases 53
Apr 20, 2010: Kineta Scientist to Present Novel Antiviral Research Findings at International Conference 53
Appendix 54
Methodology 54
Coverage 54
Secondary Research 54
Primary Research 54
Expert Panel Validation 54
Contact Us 54
Disclaimer 55

List of Tables

Number of Products under Development for West Nile Virus Infections, H1 2015 8
Number of Products under Development for West Nile Virus Infections - Comparative Analysis, H1 2015 9
Number of Products under Development by Companies, H1 2015 10
Number of Products under Investigation by Universities/Institutes, H1 2015 11
Comparative Analysis by Clinical Stage Development, H1 2015 12
Comparative Analysis by Early Stage Development, H1 2015 13
Products under Development by Companies, H1 2015 14
Products under Investigation by Universities/Institutes, H1 2015 15
West Nile Virus Infections - Pipeline by BioDiem Ltd, H1 2015 16
West Nile Virus Infections - Pipeline by CalAsia Pharmaceuticals, Inc., H1 2015 17
West Nile Virus Infections - Pipeline by CEL-SCI Corporation, H1 2015 18
West Nile Virus Infections - Pipeline by GlaxoSmithKline plc, H1 2015 19
West Nile Virus Infections - Pipeline by Kineta, Inc., H1 2015 20
Assessment by Monotherapy Products, H1 2015 21
Number of Products by Stage and Target, H1 2015 23
Number of Products by Stage and Mechanism of Action, H1 2015 25
Number of Products by Stage and Route of Administration, H1 2015 26
Number of Products by Stage and Molecule Type, H1 2015 28
West Nile Virus Infections Therapeutics - Recent Pipeline Updates, H1 2015 50
West Nile Virus Infections - Dormant Projects, H1 2015 51
West Nile Virus Infections - Dormant Projects (Contd..1), H1 2015 52